

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
CY	*	1 08/948,149		Fendly et al.			09.10.97
	*	2 09/119,152		Fendly et al.			20.07.98
	*	3 09/266,706		Fendly et al.			11.03.99
	*	4 4,753,894	28.06.88	Frankel et al.			
	*	5 4,935,341	19.06.90	Bargmann et al.			
	*	6 4,943,533	24.07.90	Mendelsohn et al.			
	*	7 4,968,603	06.11.90	Slamon et al.			
	*	8 4,975,278	04.12.90	Senter, P. et al.			
	*	9 5,169,774	08.12.92	Frankel et al.			
	*	10 5,183,884	02.02.93	Kraus et al.			
	*	11 5,288,477	22.02.94	Bacus, S.			
	*	12 5,367,060	22.11.94	Vandlen et al.			
	*	13 5,401,638	28.03.95	Carney et al.			06.03.92
	*	14 5,464,751	07.11.95	Greene et al.			
	*	15 5,480,968	02.01.96	Kraus et al.			
	*	16 5,578,482	26.11.96	Lippman et al.			
	*	17 5,604,107	18.02.97	Carney et al.			
	*	18 5,641,869	24.06.97	Vandlen et al.			03.05.95
	*	19 5,663,144	02.09.97	Greene et al.			
	*	20 5,677,171	14.10.97	Hudziak et al.			
	*	21 5,705,157	06.01.98	Greene			
	*	22 5,720,937	24.02.98	Hudziak et al.			
	*	23 5,720,954	24.02.98	Hudziak et al.			
	*	24 5,725,856	10.03.98	Hudziak et al.			06.06.95
	*	25 5,726,023	10.03.98	Cheever et al.			
	*	26 5,728,687	17.03.98	Bissery			
	*	27 5,747,261	05.05.98	King et al.			
	*	28 5,770,195	23.06.98	Hudziak et al.			
	*	29 5,772,997	30.06.98	Hudziak et al.			
	*	30 5,776,427	07.07.98	Thorpe et al.			
	*	31 5,783,186	21.07.98	Arakawa et al.			31.03.95
	*	32 5,801,005	01.09.98	Cheever et al.			
	*	33 5,821,337	13.10.98	Carter et al.			
	*	34 5,824,311	20.10.98	Greene et al.			
	*	35 5,834,229	10.11.98	Vandlen et al.			
	*	36 5,837,243	17.11.98	Deo et al.			

Date Considered

11-5-02

Examiner

Chrisysn X

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449					U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1053R1D1	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)					Applicant Fendly		
					Filing Date 02 Nov 2000	Group not yet assigned	

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
CY	*	37 5,837,523	17.11.98	Greene et al.			
	*	38 5,840,525	24.11.98	Vandlen et al.			
	*	39 5,846,538	08.12.98	Cheever et al.			
	*	40 5,856,110	05.01.99	Vandlen et al.			
	*	41 5,859,206	12.01.99	Vandlen et al.			
	*	42 5,869,445	09.02.99	Cheever et al.			
	*	43 5,876,712	02.03.99	Cheever et al.			
	*	44 5,877,305	02.03.99	Huston et al.			
	*	45 5,908,835	01.06.99	Bissery			
	*	46 5,910,486	08.01.99	Curiel et al.			
	*	47 5,922,845	13.07.99	Deo et al.			
	*	48 5,939,531	17.08.99	Wels et al.			
	*	49 5,977,322	02.11.99	Marks et al.			
	*	50 5,985,553	16.11.99	King et al.			
	*	51 6,015,567	18.01.00	Hudziak et al.			
	*	52 6,028,059	22.02.00	Curiel et al.			
	*	53 6,054,297	25.04.00	Carter et al.			
	*	54 6,054,561	25.04.00	Ring			07.06.95
CY	*	55 6,123,939	26.09.00	Shawver et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
CY	*	56 599,274	01.06.94	EPO				
	*	57 616,812	28.09.94	EPO				
	*	58 711,565	26.08.98	EPO				
	*	59 2,895,105B2	21.08.91	JAPAN (ENGLISH ABSTRACT AND CLAIMS)				
	*	60 2761543B2	08.06.90	JAPAN (ENGLISH ABSTRACT AND CLAIMS)				
	*	61 95006982B2	19.05.87	JAPAN (ENGLISH ABSTRACT AND CLAIMS)				
	*	62 3-240498	25.10.91	JP (ENGLISH ABSTRACT ATTACHED)				
	*	63 5-117165	14.05.93	JP (ENGLISH ABSTRACT ATTACHED)				
	*	64 5-170667	09.07.93	JP (ENGLISH ABSTRACT ATTACHED)				
	*	65 5-213775	24.08.93	JP (ENGLISH ABSTRACT ATTACHED)				
	*	66 5-317084	03.12.93	JP (ENGLISH ABSTRACT ATTACHED)				
	*	67 7-59588	07.03.95	JP (ENGLISH ABSTRACT ATTACHED)				
	*	68 WO 89/06692	27.07.89	PCT				
CY	*	69 WO 92/10573	25.06.92	PCT				

Examiner <i>Christopher H Y</i>	Date Considered <i>11-5-02</i>
------------------------------------	-----------------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1053R1D1	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fendly	
				Filing Date 02 Nov 2000	Group not yet assigned

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
CY	* 70	WO 93/12220	24.06.93	PCT				
	* 71	WO 93/21232	28.10.93	PCT				
	* 72	WO 93/21319	28.10.93	PCT				
	* 73	WO 94/00136	06.01.94	PCT				
	* 74	WO 94/22478	13.10.94	PCT				
	* 75	WO 94/28127	08.12.94	PCT				
	* 76	WO 95/16051	15.06.95	PCT				
	* 77	WO 95/17507	29.06.95	PCT				
	* 78	WO 95/28485	26.10.95	PCT				
	* 79	WO 96/18409	20.06.96	PCT				
	* 80	WO 97/20858	12.06.97	PCT				
	* 81	WO 97/27848	07.08.97	PCT				
	* 82	WO 97/38731	23.10.97	PCT				
	* 83	WO 98/45479	15.10.98	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

CY	* 84	Aasland et al., "Expression of oncogenes in thyroid tumours: Coexpression of c-erbB2/neu and c-erbB" <u>British Journal of Cancer</u> 57(4):358-363 (Apr 1988)
	* 85	Adams and Weiner, "Intracellular single-chain Fv antibodies--a knockout punch for neoplastic cells?" <u>Gynecologic Oncology</u> 59(1):6-7 (Oct 1995)
	* 86	Arboleda et al., "Effects of the 4D5 antibody on HER2/neu heterodimerization with other class I receptors in human breast cancer cells" <u>Proceedings of the American Association for Cancer Research</u> (Abstract #353) 37:51 (Mar 1996)
	* 87	Arteaga et al., "p185c-erbB-2 Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair" <u>Cancer Research</u> 54(14):3758-3765 (Jul 15, 1994)
	* 88	Bacus et al., "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/neu Antigen" <u>Molecular Carcinogenesis</u> 3(6):350-362 (1990)
	* 89	Bacus et al., "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells" <u>Cancer Research</u> 52(9):2580-2589 (May 1, 1992)
	* 90	Baselga et al., "Anti HER2 Humanized Monoclonal Antibody (MAB) Alone and in Combination with Chemotherapy Against Human Breast Carcinoma Xenografts" <u>Proceedings of ASCO-13th Annual Meeting</u> (Abstract #53), Dallas, TX 13:63 (Mar 1994)
	* 91	Baselga et al., "HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications" <u>Oncology</u> 11(3 Suppl 2):43-48 (Mar 1997)
	* 92	Baselga et al., "Monoclonal antibodies directed against growth factor receptors enhance the efficacy of chemotherapeutic agents" <u>Annals of Oncology</u> (abstract #010) 5(Suppl. 5) (1994)
	* 93	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185 ^{HER2} Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996)
CY	* 94	Baselga et al., "Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy" <u>Pharmac. Ther.</u> 64:127-154 (1994)

Examiner Chun-yen X Date Considered 11-5-02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1053R1D1	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fendly	
				Filing Date 02 Nov 2000	Group not yet assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
CY	* 95	Baselga et al., "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" <u>Cancer Research</u> 58:2825-2831 (July 1998)			
	* 96	Borst et al., "Oncogene Alterations in Endometrial Carcinoma" <u>Gynecologic Oncology</u> 38(3):364-366 (Sep 1990)			
	* 97	Carraway et al., "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling" <u>Cell</u> 78:5-8 (Jul 15, 1994)			
	* 98	Carter et al., "Humanization of an anti-p185HER2 antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (May 1992)			
	* 99	Cohen et al., "Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract" <u>Oncogene</u> 4(1):81-88 (Jan 1989)			
	* 100	D'souza et al., "Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene" <u>Proc. Natl. Acad. Sci. USA</u> 91(15):7202-7206 (Jul 19, 1994)			
	* 101	Darzynkiewicz et al., "Features of apoptotic cells measured by flow cytometry" <u>Cytometry</u> 13(8):795-808 (1992)			
	* 102	De Santes et al., "Radiolabeled Antibody Targeting of the HER-2/neu Oncoprotein" <u>Cancer Research</u> 52:1916-1923 (1992)			
	* 103	Deshane et al., "Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis" <u>Cancer Gene Therapy</u> 3(2):89-98 (Mar-Apr 1996)			
	* 104	Deshane et al., "Intracellular antibody knockout of the ERBB2 oncprotein achieves targeted eradication of tumor targets by induction of apoptosis" <u>Journal of Investigative Medicine</u> 43(Suppl. 2):328A (1995)			
	* 105	Deshane et al., "Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody" <u>Gynecologic Oncology</u> 59(1):8-14 (Oct 1995)			
	* 106	Deshane et al., "Targeted tumor killing via an intracellular antibody against erbB-2" <u>Journal of Clinical Investigation</u> 96(6):2980-2989 (Dec 1995)			
	* 107	Deshane et al., "Transductional Efficacy and Safety of an Intraperitoneally Delivered Adenovirus Encoding an Anti-erbB-2 Intracellular Single-Chain Antibody for Ovarian Cancer Gene Therapy" <u>Gynecologic Oncology</u> 64(3):378-385 (Mar 1997)			
	* 108	Diglesi et al., "Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER2" <u>Hybridoma</u> 11(4):519-527 (Aug 1992)			
* 109	Drebin et al., "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies" <u>Cell</u> 41(3):695-706 (Jul 1985)				
* 110	Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen" <u>Proc. Natl. Acad. Sci.</u> 83:9129-9133 (1986)				
* 111	Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo" <u>Oncogene</u> 2:273-277 (1988)				
* 112	Drebin et al., "Monoclonal Antibodies Specific for the neu Oncogene Product Directly Mediate Anti-tumor Effects In Vivo" <u>Oncogene</u> 2(4):387-394 (1988)				
↓	* 113	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)			
CY	* 114	Fraker and Speck Jr., "Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril" <u>Biochemical & Biophysical Research Communications</u> 80(4):849-857 (Feb 28, 1978)			
Examiner <i>Chris Yeh Yn</i>			Date Considered 11-5-02		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1053R1D1	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fendly	Filing Date 02 Nov 2000
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
CY	*115	Fukushige et al., "Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line" <u>Molecular & Cellular Biology</u> 6(3):955-958 (Mar 1986)			
	*116	(Genentech, Inc. Proposal Request and Material Transfer Agreement with Richard H. Scheuermann (1993), 3 pages, and letters in relation to it dated June 23, 1993 and October 20, 1993)			
	*117	Grim et al., "The level of erbB2 expression predicts sensitivity to the cytotoxic effects of an intracellular anti-erbB2 sFv" <u>Journal of Molecular Medicine</u> 76(6):451-458 (May 1998)			
	*118	Groenen et al., "Structure-Function Relationships for the EGF/TGF- α Family of Mitogens" <u>Growth Factors</u> 11:235-257 (1994)			
	*119	Guerin et al., "Overexpression of Either c-myc or c-erbB-2/neu Proto-oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis" <u>Oncogene Research</u> 3(1):21-31 (1988)			
	*120	Hancock et al., "A Monoclonal Antibody against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines" <u>Cancer Research</u> 51:4575-4580 (Sep 1, 1991)			
	*121	Harwerth et al., "Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists" <u>Journal of Biological Chemistry</u> 267(21):15160-15167 (Jul 25, 1992)			
	*122	"Herceptin (Trastuzumab)" <u>Product Information</u> (2000)			
	*123	Hudziak et al., "Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells" <u>Proc. Natl. Acad. Sci.</u> 84(20):7159-7163 (Oct 1987)			
	*124	Hudziak et al., "p185HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular & Cellular Biology</u> 9(3):1165-1172 (Mar 1989)			
	*125	Hynes and Stern, "The biology of erbB-2/neu/HER-2 and its role in cancer" <u>Biochimica et Biophysica Acta</u> 1198(2-3):165-184 (Dec 30, 1994)			
	*126	Ilgen et al., "Characterization of anti-HER/2 antibodies which inhibit the growth of breast tumor cells in vitro" <u>Proceedings of the American Association for Cancer Research</u> (abstract #3209) 37:470 (Mar 1996)			
	*127	Ilgen et al., "Characterization of anti-HER/2 monoclonal antibodies which inhibit the growth of breast cancer cell lines in vitro" <u>Proceedings of the American Association for Cancer Research</u> (Abstract #564) 38:84 (Mar 1997)			
	*128	Kasprzyk et al., "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies" <u>Cancer Research</u> 52(10):2771-2776 (May 15, 1992)			
	*129	Kern et al., "p185neu Expression in Human Lung Adenocarcinomas Predicts Shortened Survival" <u>Cancer Research</u> 50(16):5184-5191 (Aug 15, 1990)			
	*130	King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" <u>Science</u> 229:974-976 (Sept 1985)			
	*131	Kita et al., "ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies" <u>Biochemical & Biophysical Research Communications</u> 226(1):59-69 (Sep 4, 1996)			
	*132	Klapper et al., "A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors" <u>Oncogene</u> 14:2099-2109 (1997)			
	*133	Kotts et al., "Differential Growth Inhibition of Human Carcinoma Cells Exposed to Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" <u>In Vitro</u> (Abstract #176) 26(3):59A (1990)			
CY	*134	Kotts et al., "Differential Growth Inhibition of Human Carcinoma Cells Exposed to Monoclonal Antibodies Directed Against the Extracellular Domain of the HER2/ERBB2 Protooncogene" (poster presented at the Annual Meeting of the Tissue Culture Association held in Houston, Texas on June 1990) pps. 1-13			
Examiner	<i>Christopher H.Y.</i>			Date Considered 11-5-02	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1053R1D1	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Fendly		
		Filing Date 02 Nov 2000	Group not yet assigned	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
CY	*135	Kott et al., "Growth Inhibition of Human Breast Carcinoma Cells Exposed to Combinations of Interferon-Gamma and Monoclonal Antibodies Directed Against the Extracellular Domain of the Her2/erbB2 Oncogene Protein" <u>FASEB Journal</u> (abstract #1470) 4(7):A1946 (1990)		
	*136	Kumar et al., "Regulation of Phosphorylation of the c-erbB-2/HER2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells" <u>Molecular & Cellular Biology</u> 11(2):979-986 (Feb 1991)		
	*137	Lee et al., "Transforming Growth Factor α : Expression, Regulation, and Biological Activities" <u>Pharmacological Reviews</u> 47(1):51-85 (Mar 1995)		
	*138	Lemke,G., "Neuregulins in Development" <u>Molecular and Cellular Neuroscience</u> 7:247-262 (1996)		
	*139	Levi et al.. "The Influence of Heregulins on Human Schwann Cell Proliferation" <u>J. Neuroscience</u> 15(2):1329-1340 (Feb 1995)		
	*140	Lewis et al., "Differential responses of human tumor cell lines to anti-p185 ^{HER2} monoclonal antibodies" <u>Cancer Immunol. Immunother.</u> 37:255-263 (1993)		
	*141	Lewis et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" <u>Cancer Research</u> 56:1457-1465 (Mar 15, 1996)		
	*142	Maier et al., "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/neu Gene Product c-erbB-2" <u>Cancer Research</u> 51(19):5361-5369 (Oct 1, 1991)		
	*143	Marth et al., "Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells" <u>International Journal of Cancer</u> 50(1):64-68 (Jan 2, 1992)		
	*144	Masui et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies" <u>Cancer Research</u> 44(3):1002-1007 (Mar 1984)		
	*145	Masuko et al., "A murine Monoclonal Antibody That Recognizes an Extracellular Domain of the Human c-erbB-2 Protooncogene Product" <u>Jpn J. Cancer Res.</u> 80:10-14 (January 1989)		
	*146	McCann et al., "c-erbB-2 Oncoprotein Expression in Primary Human Tumors" <u>Cancer</u> 65(1):88-92 (Jan 1, 1990)		
	*147	McKenzie et al., "Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185" <u>Oncogene</u> 4:543-548 (1989)		
	*148	Mendelsohn et al., "Receptor blockade and chemotherapy: a new approach to combination cancer therapy" <u>Annals of Oncology</u> (abstract #040) 7(Suppl. 1):22 (1996)		
	*149	Moore et al., "Apoptosis in CHO Cell Batch Cultures: Examination by Flow Cytometry" <u>Cytotechnology</u> 17:1-11 (1995)		
	*150	Morrissey et al., "Axon-induced mitogenesis of human Schwann cells involves heregulin and p185 ^{erbB2} " <u>Proc. Natl. Acad. Sci. USA</u> 92:1431-1435 (Feb 1995)		
	*151	Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185 ^{neu} " <u>Methods in Enzymology</u> 198:277-290 (1991)		
	*152	Norton, L, "Evolving concepts in the systemic drug therapy of breast cancer" <u>Seminars in Oncology</u> 24(4 Suppl 10):S10-3-S10-10 (Aug 1997)		
↓	*153	Park et al., "Amplification, Overexpression, and Rearrangement of the erbB-2 Protooncogene in Primary Human Stomach Carcinomas" <u>Cancer Research</u> 49(23):6605-6609 (Dec 1, 1989)		
CY	*154	Pegram et al., "Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers" <u>Oncogene</u> 18:2241-2251 (1999)		
Examiner	<i>Christopher H Y</i>		Date Considered	11-5-02
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1053R1D1	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Fendly		
		Filing Date 02 Nov 2000	Group not yet assigned	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
CY	*155	Picker et al., "Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selectin on T cells during the virgin to memory cell transition" <u>Journal of Immunology</u> 150(3):1105-1121 (Feb 1, 1993)		
	*156	Pietras et al., "Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells" <u>Oncogene</u> 9:1829-1838 (1994)		
	*157	Plowman et al., "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4" <u>Nature (Letters to Nature)</u> 366:473-475 (Dec 2, 1993)		
	*158	Plowman et al., "Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family" <u>Proc. Natl. Acad. Sci. USA</u> 90:1746-1750 (Mar 1993)		
	*159	Price et al., "Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice" <u>Cancer Research</u> 50(3):717-721 (Feb 1, 1990)		
	*160	Raefsky et al., "Phase II Trial of Docetaxel and Herceptin as First- or Second-Line Chemotherapy for Women with Metastatic Breast Cancer Whose Tumors Overexpress HER2" <u>Proceedings of ASCO (Abstract #523)</u> 18:137a (1999)		
	*161	Ring et al., "Distribution and Physical Properties of BCA200, a Mr 200,000 Glycoprotein Selectively Associated with Human Breast Cancer" <u>Cancer Research</u> 49:3070-3080 (Jun 1, 1989)		
	*162	Ring et al., "Identity of BCA200 and c-erbB-2 Indicated by Reactivity of Monoclonal Antibodies with Recombinant c-erbB-2" <u>Molecular Immunology</u> 28(8):915-917 (1991)		
	*163	Rodeck et al., "Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors" <u>J. Cellular Biochem.</u> 35(4):315-320 (1987)		
	*164	Sarup et al., "Characterization of an Anti-P185HER2 Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth" <u>Growth Regulation</u> 1:72-82 (1991)		
	*165	Scheuermann, R., "Anti-HER2 Effects" (slide which may have been (but was probably not) presented at a seminar by Scheuermann at Syntex on August 3, 1994)		
	*166	Schlom, J., "Monoclonal Antibodies: They're More and Less Than You Think" <u>Molecular Foundations of Oncology</u> , Broder, S. ed., Baltimore, MD:Williams & Wilkins, Chapter 6, pps. 95-134 (1991)		
	*167	Scott et al., "p185HER2 Signal Transduction in Breast Cancer Cells" <u>Journal of Biological Chemistry</u> 266(22):14300-14305 (Aug 5, 1991)		
	*168	Shawver et al., "Ligand-Like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells" <u>Cancer Research</u> 54(5):1367-1373 (Mar 1, 1994)		
	*169	Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic" <u>J. Clin. Immunol.</u> 11(3):117-127 (1991)		
	*170	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (Jan 9, 1987)		
	*171	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" <u>Science</u> 244:707-712 (May 12, 1989)		
	*172	Sliwkowski et al., "A humanized monoclonal antibody for the treatment of HER2 overexpressing breast cancer" <u>Proceedings of the American Association for Cancer Research</u> 37:625-626 (Mar 1996)		
✓	*173	Sliwkowski et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin" <u>Journal of Biological Chemistry</u> 269(20):14661-14665 (May 20, 1994)		
CY	*174	Stancovski et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth" <u>Proc. Natl. Acad. Sci. USA</u> 88(19):8691-8695 (Oct 1, 1991)		
Examiner <i>Christopher M Y</i>		Date Considered 11-5-02		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1053R1D1	Serial No. not yet assigned	
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Fendly	Filing Date 02 Nov 2000	Group not yet assigned	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
CY	*175	Tagliabue et al., "Selection of monoclonal antibodies which induce internalization and phosphorylation of p185 ^{HER2} and growth inhibition of cells with HER2/NEU gene amplification" <u>International Journal of Cancer</u> 47(6):933-937 (Apr 1, 1991)			
	*176	Trauth et al., "Monoclonal antibody-mediated tumor regression by induction of apoptosis" <u>Science</u> 245:301-305 (1989)			
	*177	Vitetta et al., "Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy" <u>Cancer Research</u> 54(20):5301-5309 (Oct 15, 1994)			
	*178	Vollmers et al., "Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody" <u>Cancer</u> 76(4):550-558 (Aug 15, 1995)			
	*179	Weiner et al., "Expression of the neu Gene-encoded Protein (P185 ^{neu}) in Human Non-Small Cell Carcinomas of the Lung" <u>Cancer Research</u> 50(2):421-425 (Jan 15, 1990)			
	*180	Weller et al., "Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines" <u>Journal of Clinical Investigation</u> 94(3):954-964 (Sep 1994)			
	*181	Williams et al., "Expression of c-erbB-2 in Human Pancreatic Adenocarcinomas" <u>Pathobiology</u> 59(1):46-52 (1991)			
	*182	Wright et al., "An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2" <u>Gene Therapy</u> 4(4):317-322 (Apr 1997)			
	*183	Wu et al., "Apoptosis Induced By an Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in a Human Colorectal Carcinoma Cell Line and Its Delay By Insulin" <u>Journal of Clinical Investigation</u> 95(4):1897-1905 (Apr 1995)			
	*184	Xu et al., "Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185" <u>International Journal of Cancer</u> 53(3):401-408 (Feb 1, 1993)			
	*185	Yamamoto et al., "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor" <u>Nature</u> 319:230-234 (1986)			
	*186	Yokota et al., "Amplification of c-erbB-2 Oncogene in Human Adenocarcinomas in Vivo" <u>Lancet</u> 1(8484):765-767 (Apr 5, 1986)			
	*187	Yonemura et al., "Evaluation of Immunoreactivity for erbB-2 Protein as a Marker of Poor Short Term Prognosis in Gastric Cancer" <u>Cancer Research</u> 51(3):1034-1038 (Feb 1, 1991)			
	*188	Zhang et al., "Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis" <u>Invasion Metastasis</u> 11(4):204-215 (1991)			
	*189	Zhang et al., "Shared antigenic epitopes and pathobiological functions of anti-p185 ^{her2/neu} monoclonal antibodies" <u>Experimental and Molecular Pathology</u> 67:15-25 (1999)			
	CY	*190	Zhau et al., "Amplification and Expression of the c-erb B-2/neu Proto-Oncogene in Human Bladder Cancer" <u>Molecular Carcinogenesis</u> 3(5):254-257 (1990)		
	Examiner <i>Christopher M Yuen</i>		Date Considered 11-5-02		
	*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				